Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deborah J. Wexler MD, MSc Associate Editor

See All Experts

featured

Published in Diabetes and

Journal Scan / Research · March 27, 2024

Efficacy and Safety of Tirzepatide, GLP-1 Receptor Agonists, and Other Weight Loss Drugs in Overweight and Obesity

Obesity

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

Obesity

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

Obesity 2024 Feb 27;[EPub Ahead of Print], XH Pan, B Tan, YH Chin, ECZ Lee, G Kong, B Chong, M Kueh, CM Khoo, A Mehta, P Majety, GR Grandhi, GK Dimitriadis, R Foo, NWS Chew, CW Le Roux, MA Mamas, MY Chan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Efficacy and Safety of Tirzepatide, GLP-1 Receptor Agonists, and Other Weight Loss Drugs in Overweight and Obesity

Additional Info

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

Further Reading

Effect of Insulin Type (Ultra-Rapid Vs Rapid Insulin) and Exercise Timing on Postprandial Exercise–Induced Hypoglycaemia Risk in Individuals With Type 1 Diabetes

Gastric Bypass Elicits Persistent Gut Adaptation and Unique Diabetes Remission–Related Metabolic Gene Regulation

Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in People With Diabetes and Advanced Chronic Kidney Disease

Prognostic Significance of Diabetes in Patients With NSCLC Treated With Immune Checkpoint Inhibitors

Real-World Effectiveness of Oral Semaglutide in Adults and Older Individuals With Type 2 Diabetes

Effect of Combined Use of SGLT2 Inhibitors and Pioglitazone on the Risk of MASH in Individuals With Type 2 Diabetes

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Implications of Continuous Ketone Monitoring in Clinical Practice

Characterizing the Effects of Using GLP-1 Receptor–Based Agonists on Body Composition

The SEAD Program Improved Clinical Outcomes in Underserved Young Adults With Type 1 Diabetes

Predicting Hypoglycemia and Hyperglycemia Risks During and After Physical Activity in Adolescents With Type 1 Diabetes

Recently Updated